Saturday 17 October 2026
Export PHR’s income statement to Excel — free account
Phreesia, Inc.
PHR Healthcare Health Information Services
Phreesia, Inc.’s revenue for fiscal 2026 (year ended January 2026) was $480.6 million, up 14.5% from fiscal 2025. In the quarter to July 2026, revenue grew 10.4%, EPS grew 200.0%, free cash flow grew 43.5% and total debt rose 3,191.9%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
10.94
0.10
−0.91%
Follow PHR
| Older periods | Oct '25 | Jan '26 | Apr '26 | Jul '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 440.33 | 61.40 | 63.12 |
P/S ratio |
2.93 | 1.64 | 1.13 | 1.31 | |
P/FCF ratio |
38.72 | 14.50 | 8.86 | 9.83 | |
P/Operating CF |
87.84 | 23.44 | 23.46 | 36.23 | |
P/B ratio |
4.24 | 2.34 | 1.56 | 1.79 | |
Price to Tangible BV |
6.21 | 9.03 | 4.99 | 5.28 | |
EV/Sales |
2.73 | 1.85 | 1.34 | 1.46 | |
EV/EBITDA |
60.89 | 31.38 | 15.83 | 13.86 | |
EV/Operating CF |
20.57 | 11.30 | 7.54 | 8.12 | |
EV/FCF |
35.99 | 16.37 | 10.47 | 10.98 | |
Quick Ratio |
1.97 | 1.25 | 1.43 | 1.44 | |
Current Ratio |
2.44 | 1.53 | 1.76 | 1.76 | |
Net Debt/EBITDA |
(9.05) | 14.46 | 5.90 | 4.35 | |
Debt/Assets |
0.79% | 26.44% | 26.49% | 23.28% | |
Debt/Equity |
0.01 | 0.52 | 0.49 | 0.41 | |
Asset Turnover |
1.16 | 0.91 | 0.93 | 0.96 | |
Operating CF/Net income |
3.62 | 25.99 | 8.07 | 9.56 | |
Capex/Depreciation |
(0.87) | (0.41) | (0.72) | (0.44) | |
Interest Coverage |
— | (0.91) | 2.94 | 4.40 | |
Research and Development Expense of Revenue |
24.48% | 24.34% | 21.64% | 21.30% | |
Selling, General and Administrative Expense of Revenue |
34.60% | 40.63% | 32.51% | 31.75% | |
Intangible Assets out of Total Assets |
0.24 | 0.38 | 0.37 | 0.38 | |
Share Based Compensation of Revenue |
13.26% | 14.20% | 10.35% | 9.17% | |
Graham Net Nets |
0.10 | (0.06) | (0.07) | (0.03) | |
Graham Number |
0.00 | 1.95 | 4.46 | 4.79 | |
Earnings Yield |
(0.44%) | 0.23% | 1.63% | 1.58% | |
Free Cash Flow Yield |
2.58% | 6.90% | 11.28% | 10.17% | |
Revenue per Share |
2.01 | 2.13 | 2.15 | 2.09 | |
Operating CF per Share |
0.26 | 0.56 | 0.39 | 0.30 | |
Capex per Share |
(0.11) | (0.09) | (0.12) | (0.07) | |
Free Cash Flow per Share |
0.15 | 0.48 | 0.27 | 0.22 | |
Cash per Share |
1.77 | 1.24 | 1.23 | 1.18 | |
Shareholders Equity per Share |
5.34 | 5.64 | 5.89 | 6.01 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.34 | 5.64 | 5.89 | 6.01 | |
Free Cash Flow |
8.80 | 28.53 | 16.37 | 13.82 | |
Working Capital |
142.12 | 96.60 | 115.15 | 109.67 | |
Capital Expenditures |
(6.67) | (5.14) | (7.55) | (4.50) | |
Net Current Asset Value |
137.76 | (46.74) | (39.79) | (21.62) | |
EV/EBIT |
0.00 | 0.00 | 193.65 | 59.15 | |
Capex to Sales |
0.06 | 0.04 | 0.06 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 163.93 | 52.95 | |
| Other line items | |||||
Average Receivables |
79.83 | 114.12 | 109.20 | 105.56 | |
Average Payables |
11.04 | 8.55 | 7.55 | 9.38 | |
Average Assets |
399.59 | 526.10 | 533.27 | 527.80 | |
Average Common Equity |
287.46 | 301.01 | 320.64 | 334.92 |
Columns are period end dates